LB Pharmaceuticals
LBRX
53 hedge funds and large institutions have $315M invested in LB Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 53 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
99.18% more ownership
Funds ownership: 0% → 99.18% (+99%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$53.2M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$28.2M |
| 3 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$27.7M |
| 4 |
CC
Commodore Capital
New York
|
+$23.8M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
+$17.9M |
Top Sellers
LBRX Hedge Fund Activity: Q3 2025 in Review
53 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in LB Pharmaceuticals (LBRX) for Q3 2025, worth a combined $315M.
Buyers outnumbered sellers: 53 funds opened new LBRX positions and 0 closed out — a net gain of 53 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $53.2M.
- 53 institutional investors held LB Pharmaceuticals (LBRX) as of Q3 2025, up from 0 in Q2 2025.
- Funds reported $315M of LB Pharmaceuticals stock for Q3 2025.
- 53 funds opened new LB Pharmaceuticals positions in Q3 2025 and 0 closed out, a net change of +53 holders.
- The largest LB Pharmaceuticals buyer in Q3 2025 was Deep Track Capital, an estimated $53.2M added.
Based on aggregated 13F filings for Q3 2025.